The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 2 , Pages 408-416.e1 , August 2010

Pioglitazone preserves vein graft integrity in a rat aortic interposition model

  • Zhi Chen, MD
    • ,
  • Tomomi Hasegawa, MD, PhD
    • ,
  • Akiko Tanaka, MD
    • ,
  • Yutaka Okita, MD, PhD
    • ,
  • Kenji Okada, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress for reprints: Kenji Okada, MD, PhD, Department of Surgery, Division of Cardiovascular Surgery, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.

Received 2 September 2009 ,Revised 10 November 2009 ,Accepted 27 November 2009.

References 

  1. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431–1438
  2. Goldman J, Zhong L, Liu SQ. Degradation of alpha-actin filaments in venous smooth muscle cells in response to mechanical stretch. Am J Physiol Heart Circ Physiol. 2003;284:H1839–H1847
  3. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106–1118
  4. Abdelrahman M, Sivarajah A, Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res. 2005;65:772–781
  5. Kasai T, Miyauchi K, Yokoyama T, Kajimoto K, Sumiyoshi K, Kubota N, et al. Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting. Atherosclerosis. 2008;197:612–619
  6. Aizawa Y, Kawabe J, Hasebe N, Takehara N, Kikuchi K. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation. 2001;104:455–460
  7. Nakamura T, Yamamoto E, Kataoka K, Yamashita T, Tokutomi Y, Dong YF, et al. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension. 2008;51:296–301
  8. Yoshimoto T, Naruse M, Shizume H, Naruse K, Tanabe A, Tanaka M, et al. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis. 1999;145:333–340
  9. Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;106:3126–3132
  10. Tanaka Y, Hasegawa T, Chen Z, Okita Y, Okada K. Renoprotective immunosuppression by pioglitazone with low-dose cyclosporine in rat heart transplantation. J Thorac Cardiovasc Surg. 2009;138:744–751
  11. Haraguchi T, Okada K, Tabata Y, Maniwa Y, Hayashi Y, Okita Y. Controlled release of basic fibroblast growth factor from gelatin hydrogel sheet improves structural and physiological properties of vein graft in rat. Arterioscler Thromb Vasc Biol. 2007;27:548–555
  12. Hasegawa T, Bouis D, Liao H, Visovatti SH, Pinsky DJ. Ecto-5' nucleotidase (CD73)-mediated adenosine generation and signaling in murine cardiac allograft vasculopathy. Circ Res. 2008;103:1410–1421
  13. Huynh TT, Davies MG, Trovato MJ, Barber L, Safi HJ, Hagen PO. Reduction of lipid peroxidation with intraoperative superoxide dismutase treatment decreases intimal hyperplasia in experimental vein grafts. J Surg Res. 1999;84:223–232
  14. Shi Y, Patel S, Davenpeck KL, Niculescu R, Rodriguez E, Magno MG, et al. Oxidative stress and lipid retention in vascular grafts: comparison between venous and arterial conduits. Circulation. 2001;103:2408–2413
  15. Chung AW, Rauniyar P, Luo H, Hsiang YN, van Breemen C, Okon EB. Pressure distention compared with pharmacologic relaxation in vein grafting upregulates matrix metalloproteinase-2 and -9. J Vasc Surg. 2005;42:747–756
  16. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation. 2002;105:2296–2302
  17. Jones A, Deb R, Torsney E, Howe F, Dunkley M, Gnaneswaran Y, et al. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation. 2009;119:3125–3132
  18. Liu SQ, Moore MM, Yap C. Prevention of mechanical stretch-induced endothelial and smooth muscle cell injury in experimental vein grafts. J Biomech Eng. 2000;122:31–38
  19. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res. 2006;71:247–258
  20. Satoh K, Nigro P, Matoba T, O'Dell MR, Cui Z, Shi X, et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med. 2009;15:649–656
  21. Human P, Franz T, Scherman J, Moodley L, Zilla P. Dimensional analysis of human saphenous vein grafts: Implications for external mesh support. J Thorac Cardiovasc Surg. 2009;137:1101–1108
  22. Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res. 2008;102:283–294
  23. Yamashita K, Murakami H, Okuda T, Motohashi M. High-performance liquid chromatographic determination of pioglitazone and its metabolites in human serum and urine. J Chromatogr B Biomed Appl. 1996;677:141–146
  24. Arii K, Ota K, Suehiro T, Ikeda Y, Nishimura K, Kumon Y, et al. Pioglitazone prevents reactive hypoglycemia in impaired glucose tolerance. Diabetes Res Clin Pract. 2005;69:305–308
  25. Wohrle J, Marx N, Koenig W, Hombach V, Kestler HA, Hoher M, et al. Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease. Clin Res Cardiol. 2008;97:726–733

 Disclosures: None.

 Supported by the Japan Heart Foundation Research Grant.

PII: S0022-5223(09)01628-6

doi: 10.1016/j.jtcvs.2009.11.067

The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 2 , Pages 408-416.e1 , August 2010

Article Tools

* Image Usage & Resolution